UCB, Bicycle Therapeutics, and Sanofi share their latest findings in Peptide discovery at Biologics UK 2022.

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our April Discussion Group addressing ‘Accelerating Antibody Engineering With AI/ML & Advanced Computational Tools and Technologies’ brought together an exclusive panel of key opinion leaders to address the market’s growth and future outlook.

As market leaders in the biologics field, there is no sign of demand for antibody-based therapies slowing down any time soon. With exclusive insights from the CRUK-AstraZeneca Antibody Alliance Laboratory, we look towards the future of antibody discovery and optimisation.

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our March Discussion Group addressing ‘Sustainable Synthesis of Therapeutic Oligonucleotides’ brought together an exclusive panel of key opinion leaders to address the market’s growth and future outlook.

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our February Discussion Group addressing ‘T Cell Engagement and Redirection – Strategies, Methods, and T Cell Design’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.

With efficacy, safety, and targetability being the top three challenges facing the nucleotide-based therapeutic industry today, will oligo-based therapies fulfil their potential as a clinical modality?

The first of its kind, the Oligonucleotides: Chemistry & Therapeutics Symposium was a hit. We sat down with an advisory group of leading industry experts to hear their thoughts on the future of the Oligonucleotide drug industry as well as some of its key market trends and challenges.

Oligonucleotides are fast becoming a globally recognised form of therapeutic treatment. But how easy is it to analyse them? Director of AstraZeneca, Tomas Leek takes us through the analytic challenges of the early-stage oligonucleotide characterisation.

Stimulating T cells using bispecific antibody immunotherapies can lead to transformational clinical benefits for cancer patients. So how exactly is the industry addressing the need for targeted T cell-based immunotherapies?

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our January Discussion Group addressing ‘Peptides Green Chemistry Strategies and Methods’ was a tremendous success. The discussion brought together an exclusive panel of key opinion leaders to address the key factors behind the market’s growth, its priorities, future outlook, and challenges.